Renaissance Technologies
URGN icon

Renaissance Technologies’s UroGen Pharma URGN Stock Holding History

Renaissance Technologies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$605K Sell
14,900
-55,400
-79% -$2.38M ﹤0.01% 2555
2026
Q2 		$2.59M Buy
+70,300
New +$1.91M ﹤0.01% 1824
2026
Q1 		– Sell
-244,300
Closed -$5.72M – 3708
2025
Q4 		$5.72M Sell
244,300
-30,800
-11% -$668K 0.01% 1218
2025
Q3 		$5.49M Buy
275,100
+236,900
+620% +$4.25M 0.01% 1435
2025
Q2 		$523K Sell
38,200
-52,400
-58% -$503K ﹤0.01% 2803
2025
Q1 		$1M Sell
90,600
-47,600
-34% -$507K ﹤0.01% 2432
2024
Q4 		$1.47M Buy
+138,200
New +$1.65M ﹤0.01% 2255
2024
Q1 		– Sell
-91,300
Closed -$1.37M – 4103
2023
Q4 		$1.37M Sell
91,300
-69,000
-43% -$896K ﹤0.01% 2200
2023
Q3 		$2.25M Buy
160,300
+86,300
+117% +$1.39M ﹤0.01% 1788
2023
Q2 		$766K Buy
74,000
+26,000
+54% +$287K ﹤0.01% 2635
2023
Q1 		$444K Buy
48,000
+4,700
+11% +$43.3K ﹤0.01% 2943
2022
Q4 		$384K Buy
43,300
+200
+0.5% +$1.89K ﹤0.01% 3105
2022
Q3 		$359K Sell
43,100
-500
-1% -$4.14K ﹤0.01% 3115
2022
Q2 		$357K Buy
43,600
+18,900
+77% +$130K ﹤0.01% 3354
2022
Q1 		$215K Buy
+24,700
New +$193K ﹤0.01% 3614
2021
Q1 		– Sell
-32,800
Closed -$591K – 3728
2020
Q4 		$591K Buy
+32,800
New +$687K ﹤0.01% 2745
2019
Q2 		– Sell
-8,000
Closed -$296K – 3767
2019
Q1 		$296K Buy
+8,000
New +$335K ﹤0.01% 3098
2018
Q4 		– Sell
-16,800
Closed -$793K – 3629
2018
Q3 		$793K Sell
16,800
-98,651
-85% -$4.58M ﹤0.01% 2697
2018
Q2 		$5.74M Sell
115,451
-41,249
-26% -$2.4M 0.01% 1699
2018
Q1 		$7.79M Buy
156,700
+25,600
+20% +$1.28M 0.01% 1530
2017
Q4 		$4.88M Buy
131,100
+105,500
+412% +$3.76M 0.01% 1824
2017
Q3 		$807K Buy
+25,600
New +$565K ﹤0.01% 2645

Other funds holding URGN

ING Group
ING Group Amsterdam, Netherlands $17.7B AUM 39.02% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $16.3B AUM 54.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Renaissance Technologies's URGN Position: Q3 2026 in Review

Renaissance Technologies reduced its UroGen Pharma (URGN) stake by 79% in Q3 2026, selling an estimated $2.38M and leaving 14,900 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #2555.

Renaissance Technologies first reported a position in URGN in Q3 2017 and has held it in 22 quarters since. The position peaked at $7.79M in Q1 2018. 113 funds tracked by Wall St. Rank hold URGN as of Q3 2026.

  • Renaissance Technologies held 14,900 shares of UroGen Pharma worth $605K as of Q3 2026.
  • Renaissance Technologies sold 55,400 UroGen Pharma shares in Q3 2026, an estimated $2.38M.
  • UroGen Pharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2555 holding.
  • Renaissance Technologies first reported a position in UroGen Pharma in Q3 2017 and has held it in 22 quarters since.
  • Renaissance Technologies's UroGen Pharma position peaked at $7.79M in Q1 2018.
  • 113 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.